St. John's wort does not interfere with therapeutic drug monitoring of 12 commonly monitored drugs using immunoassays

Journal of Clinical Laboratory Analysis

Volumn 20, Issue 2, 2006, Pages 62-67

  Dasgupta, Amitava ^a   Tso, Gertie ^b   Szelei Stevens, Kathy ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b MEMORIAL HERMANN HOSPITAL   (United States)

Author keywords

Immunoassay; Interference study; St. John's wort; Therapeutic drug monitoring

Indexed keywords

ACECAINIDE; CARBAMAZEPINE; CYCLOSPORIN; CYTOCHROME P450 3A4; DIGOXIN; HYPERFORIN; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; PHENOBARBITAL; PHENYTOIN; PROCAINAMIDE; QUINIDINE; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT; TSUKUBAENOLIDE; VALPROIC ACID;

ARTICLE; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG FORMULATION; DRUG MONITORING; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; HYPERICUM PERFORATUM; IMMUNOASSAY; LIQUID; MEDICINAL PLANT; POWDER; PSYCHOPHARMACOTHERAPY; SELF MEDICATION; THERAPEUTIC DRUG MONITORING; THIN LAYER CHROMATOGRAPHY;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; ARTIFACTS; DRUG MONITORING; HERB-DRUG INTERACTIONS; HUMANS; HYPERICUM; IMMUNOASSAY; PHYTOTHERAPY;

HYPERICUM PERFORATUM;

EID: 33645512861     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.20098     Document Type: Article

References (36)

1. Gulla J, Singer AJ, Gaspari R. Herbal use in ED patients. Acad Emerg Med 2001;8:450.
2. Mannel M. Drug interactions with St. John's wort: mechanism and clinical implications. Drug Safety 2004;27:773-797.
3. Fujita K. Food-drug interactions via human cytochrome P 450 3A (CYP3A4). Drug Metabol Drug Interact 2004;20:195-217.
4. Mills E, Montori VM, Wu P, Gallicano K, Clarke M, Guyatt G. Interaction of St. John's wort with conventional drugs: systematic clinical trials. BMJ 2004;329:27-30.
5. Murphy PA, Kern SE, Stanczyk FZ, Westhoff CL. Interaction of St. John's wort with oral contraceptives: effect on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception 2005;71:402-408.
6. Martin-Facklam M, Rieger K, Riedel KD, Burhenne J, Walter-Sack I, Haefeli WE. Undeclared exposure of St. John's wort in hospitalized patients. Br J Clin Pharmacol 2004;58:437-441.
7. Barone GW, Gurley BJ, Ketel BL, Abul-Ezz SR. Herbal supplements: a potential for drug interactions in transplant recipients. Transplantation 2001;71:239-241.
8. Bauer S, Stromer E, Johne A, et al. Alteration of cyclosporine A pharmacokinetics and metabolism during treatment with St. John's wort in renal transplant patients. Br J Clin Pharmacol 2003;55:203-211.
9. Mai I, Bauer S, Perloff ES, Johne A, Uehleke B, et al. Hyperforin content determines the magnitude of the St. John's wort-cyclosporine drug interaction. Clin Pharmacol 2004;76:330-340.
10. Hebert MF, Park JM, Chen YL, et al. Effects of St John's wort (Hypercium perforatum) on tacrolimus pharmacokinetics in healthy volunteers. Clin Pharmacol 2004;44:89-94.
11. Mai I, Stormer E, Bauer S, et al. Impact of St. John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant 2003;18:819-822.
12. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Fallon J. Indinavir concentrations and St. John's wort. Lancet 2000;355:547-548.
13. Busti AJ, Hall RJ, Margolis DM. Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy 2004;24:1732-1747.
14. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2003;63:769-802.
15. Nebel A, Schneider BJ, Kroll DJ. Potential metabolic interaction between St. John's wort and theophylline. Ann Pharmacother 1999;33:502.
16. Morimoto T, Kotegawa T, Tsutsumi K, Ohtani Y, Imai H, Nakano S. Effect of St. John's wort on the pharmacokinetics of theophylline in healthy volunteers. J Clin Pharmacol 2004;44:95-101.
17. Eich-Hochli D, Oppliger R, Golay KP, Baumann P, Eap CB. Methadone maintenance treatment and St. John's wort-a case study. Pharmacopsychiatry 2003;36:35-37.
18. Smith P. The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy 2004;24:1508-1514.
19. Sugimoto K, Ohmori M, Tsuruoka S, et al. Different effect of St. John's wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 2001;70:518-524.
20. Burstein AH, Horton RL, Dunn T, Alfaro RM, Piscitelli SC, Theodore W. Lack of effect of St. John's wort on carbamazepine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 2000;68:605-612.
21. Johne A, Brockmoller J, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66:338-345.
22. Durr D, Stieger B, Kullak-Ublick GA, et al. St John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000;68:598-604.
23. Muller SC, Uehleke B, Woehling H, et al. Effect of St. John's wort dose and preparation on the pharmacokinetics of digoxin. Clin Pharmacol Ther 2004;75:546-557.
24. Tannergren C, Engman H, Knutson L, Hedeland M, Bondesson U, Lennernas H. St John's wort decreases the bioavailability of R and S-verapamil through induction of the first pass metabolism. Clin Pharmacol Ther 2004;75:298-309.
25. Panesar NS. Bufalin and unidentified substances in traditional Chinese medicine cross react in commercial digoxin assay. Clin Chem 1992;38:2155-2156.
26. Dasgupta A, Biddle D, Wells A, Datta P. Positive and negative interference of Chinese medicine Chan Su in serum digoxin measurement: elimination of interference by using a monoclonal chemiluminescent digoxin assay or monitoring free digoxin concentration. Am J Clin Pathol 2000;114:174-179.
27. Wahed A, Dasgupta A. Positive and negative in vitro interference of Chinese medicine Dan Shen in serum digoxin measurement: elimination of interference by monitoring free digoxin concentration. Am J Clin Pathol 2001;116:403-408.
28. McRae S. Elevated serum digoxin levels in a patient taking digoxin and Siberian ginseng. CMAJ 1996;155:293-295.
29. Dasgupta A, Wu S, Actor J, Olsen M, Wells A, Datta P. Effect of Asian and Siberian ginseng on serum digoxin measurement by five digoxin immunoassays: significant variation in digoxin-like immunoreactivity among commercial ginsengs. Am J Clin Pathol 2003;119:298-303.
30. Chow L, Johnson M, Wells A, Dasgupta A. Effect of traditional Chinese medicines Chan Su, Lu-Shen-Wan, DanShen and Asian ginseng on serum digoxin measurement by Tina-Quant (Roche) and Synchron LX system (Beckman) digoxin immunoassays. J Clin Lab Anal 2003;17:22-27.
31. Orth HC, Rentel C, Schmidt PC. Isolation, purity analysis and stability of hyperforin as a standard material from Hypericum perforatum L. J Pharm Pharmacol 1999;51:193-200.
32. Miller JJ, Valdes R. Methods for calculating cross reactivity in immunoassays. J Clin Immunoassay 1992;15:97-100.
33. Schempp CM, Winghofer B, Langheinrich M, Schopf E, Simon JC. Hypericin levels in human serum and interstitial skin blister fluid after oral single dose and steady state administration of Hypericum perforatum extract (St. John's wort). Skin Pharmacol Appl Skin Physiol 1999;12:299-304.
34. Staffeldt B, Kerb R, Brockmoller J, Ploch M, Roots I. Pharmacokinetics of hypericin and pseudohypericin after oral intake of Hypericium perforatum extract LI 160 in healthy volunteers. J Geriatr Psychiatry Neurol 1994;7:(Suppl 1): S47-S53.
35. Agrosi M, Mischiatti S, Harrasser PC, Savio D. Oral bioavailability of active principles from herbal products in humans: a study of Hypericum perforatum extracts using the soft gelatin capsule technology. Phytomedicine 2000;7:455-462.
36. Vitiello B, Shader RI, Parker CB, et al. Hyperforin plasma level as marker of treatment of adherence in the National Institutes of Health hypericum depression trial. Clin Psychopharmacol 2005;25:243-249.